The Final Report of a Phase 3 Trial to Study the Impact of Pretreatment FDG-PET on Cervical Cancer Patients With Positive Pelvic But Negative Para-Aortic Node Shown in MRI

Abstract

Dosimetric Comparison Based on Consensus Delineation of Clinical Target Volume for CTand MR-Based Brachytherapy in Locally Advanced Cervical Cancer A.N. Viswanathan, I. Buzurovic, A.L. Damato, W. Bosch, D. Gaffney, S. Beriwal, O. Burnett, D. D’Souza, A. Jhingran, E.L. Jones, C. Kunos, L. Lee, L. Lin, N.A. Mayr, I. Petersen, L. Portelance, W. Small, A. Wolfson, C.M. Yashar, and B. Erickson; Brigham & Women’s Hospital, Boston, MA, Washington University, St. Louis, MO, Huntsman Cancer Hospital, Salt Lake City, UT, University of Pittsburgh School of Medicine, Pittsburgh, PA, University of Alabama Medical Center, Birmingham, AL, University of Western Ontario, Ontario, ON, Canada, University of Texas MD Anderson, Houston, TX, University of North Carolina, Chapel Hill, NC, Summa Health, Akron, OH, University of Pennsylvania, Philadelphia, PA, University of Washington Medical Center, Seattle, WA, Mayo Clinic, Rochester, MN, University of Miami, Miami, FL, Loyola University Chicago, Chicago, IL, Unversity of Miami Miller School of Medicine, Miami, FL, University of California San Diego, La Jolla, CA, Medical College of Wisconsin, Milwaukee, WI